Why Clinical Requirements Change: Dr. Peter Marks on Pre-IND Meeting Pathways
Here, Dr. Peter Marks shares how clinical requirements change after the FDA and a company agree on a pathway during a pre-IND meeting. He covered why might clinical requirements change and how the company might recover as a result.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Thermo Fisher Scientific Bioproduction
This website uses cookies to ensure you get the best experience on our website. Learn more